Peptic Ulcer Drugs Market: Emerging Trends, Key Drivers, and Future Outlook

The Peptic Ulcer Drugs Market is gaining momentum as pharmaceutical innovation, gastrointestinal disease awareness, and improved access to treatment reshape the therapeutic landscape. Market Research Future estimates that the market will grow from USD 5.71 billion in 2025 to USD 9.74 billion by 2035, representing a CAGR of 5.48%. Increasing H. pylori screening, aging populations, and growing healthcare expenditure are among the factors supporting this expansion.

Peptic ulcers are commonly associated with H. pylori infection, excessive acid production, and long-term use of nonsteroidal anti-inflammatory drugs. As healthcare providers increasingly focus on early diagnosis and effective eradication therapy, demand for acid-suppressing and combination medications is expected to remain resilient.

Traditional proton pump inhibitors continue to hold a dominant position. PPIs accounted for 54.7% of market revenue in 2024, reflecting their widespread adoption and availability through both prescription and generic channels. Their established clinical profile makes them an important component of treatment strategies for gastric and duodenal ulcers.

However, the industry is gradually moving toward newer treatment classes. Potassium-competitive acid blockers are receiving greater attention because of their rapid onset, predictable acid suppression, and potential advantages in H. pylori eradication. The PCAB category is expected to grow at a 9.83% CAGR through 2035, indicating strong commercial potential.

The growing focus on H. pylori management is also creating opportunities in emerging economies. Government-supported screening programs and expanded healthcare coverage can increase the number of patients receiving diagnosis and treatment. Such initiatives may improve access to ulcer therapies while supporting pharmaceutical sales.

Digital healthcare is another emerging influence. Online pharmacies and e-commerce platforms are simplifying prescription fulfillment and recurring medication purchases. The online pharmacy and e-commerce segment is projected to expand at an 11.50% CAGR through 2035. Telemedicine and digital prescription services can further improve access for patients in underserved regions.

The competitive environment is therefore shifting toward differentiated therapies, improved adherence, and patient-centric treatment models. Pharmaceutical companies that invest in PCAB development, combination regimens, precision diagnostics, and digital health integration may gain significant opportunities. With North America currently leading regional revenue and Asia-Pacific showing the highest expected growth rate, the market is positioned for continued development throughout the forecast period.